Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

B-902

Supelco

Buprenorphin -Lösung

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C29H41NO4
CAS-Nummer:
52485-79-7
Molekulargewicht:
467.64
EG-Nummer:
200-659-6
UNSPSC-Code:
41116107

Qualität

certified reference material

Qualitätsniveau

300

Form

liquid

Leistungsmerkmale

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Konzentration

100 μg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

forensics and toxicology

Format

single component solution

Lagertemp.

2-8°C

SMILES String

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

InChIKey

RMRJXGBAOAMLHD-IHFGGWKQSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

Sold under the trade names Buprenex®, Subutex® and Suboxone®, buprenorphine is an opiate drug used to treat opioid addiction and moderate acute pain. This Certified Spiking Solution® standard is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or pharmaceutical research.

Anwendung


  • Research on Addiction and Implementation Challenges: Buprenorphine solutions have been crucial in studies exploring how systemic barriers affect the implementation of addiction treatments during concurrent public health crises, offering insights valuable for policy and practice adjustments in healthcare systems (Sharp et al., 2023).

  • Evaluating Patient-Important Measures in Opioid Use Disorder Treatments: Buprenorphine is used extensively to evaluate patient-important outcomes in medication-assisted treatment programs for opioid use disorders, aiding in the assessment of long-term recovery metrics and treatment efficacy (Reed et al., 2023).

  • Web-Based Substance Use Epidemiology Research: Buprenorphine research solutions are instrumental in developing web-based ontologies for tracking and analyzing drug abuse trends, providing a foundational tool for public health surveillance and policy-making in substance abuse epidemiology (Lokala et al., 2022).

  • Clinical Studies in Veterinary Medicine: Buprenorphine solutions are employed in veterinary medicine to assess the efficacy of transdermal applications for managing postoperative pain in animals, demonstrating its versatility and effectiveness across different biological systems (Clark et al., 2022).

  • Pain Management in Geriatric Orthopedics: The use of transdermal buprenorphine for managing pain following femur fractures in elderly patients highlights its critical role in improving postoperative care and enhancing recovery outcomes in geriatric orthopedics (Davies et al., 2022).

Rechtliche Hinweise

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

B-035

Buprenorphin-Glucuronid -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

Buprenorphin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphin-D4 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphin-D4 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Glucuronid-Norbuprenorphin -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

Norbuprenorphin -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphin-D3 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphin-D3 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

EU REACH Annex XVII (Restriction List)

CAS No.

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 8

1 of 8

Dodecyltrimethylammoniumbromid BioXtra, ~99%

Sigma-Aldrich

D5047

Dodecyltrimethylammoniumbromid

Oxycodon -Lösung 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-002

Oxycodon -Lösung

(±)-MDMA -Lösung 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-013

(±)-MDMA -Lösung

Supelco

Supelco

H-003

Hydrocodon -Lösung

(±)-Methamphetamin -Lösung 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-009

(±)-Methamphetamin -Lösung

(±)-Methadon -Lösung 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-007

(±)-Methadon -Lösung

Myristyltrimethylammoniumbromid ≥99%

Sigma-Aldrich

T4762

Myristyltrimethylammoniumbromid

Natriumchlorid -Lösung 0.9% in water, BioXtra, suitable for cell culture

Sigma-Aldrich

S8776

Natriumchlorid -Lösung

E J Love et al.
The Veterinary record, 172(24), 635-635 (2013-06-06)
Buprenorphine has recently obtained UK Marketing Authorisation for horses. The analgesic effects are long lasting, and have considerable potential for postoperative pain relief. This observer blinded, randomised study aimed to evaluate postsurgical analgesia in ponies premedicated with buprenorphine prior to
O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
P M J Clement et al.
Acta clinica Belgica, 68(2), 87-91 (2013-08-24)
Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented
Jatinder Mohan Chawla et al.
Journal of opioid management, 9(1), 35-41 (2013-05-28)
Tramadol is a synthetic opiate and a centrally acting weak m-opioid receptor agonist. The potential advantages of tramadol include ease of administration, low abuse potential, and being nonscheduled. This study compared tramadol and buprenorphine for controlling withdrawal symptoms in patients
K Wahle et al.
MMW Fortschritte der Medizin, 155 Suppl 1, 25-31 (2013-05-18)
Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.